How These Biotech Stocks are Performing? -- Intrexon, 22nd Century, Corcept Therapeutics, and Achaogen

NEW YORK, July 26, 2017 /PRNewswire/ --

If you want a Stock Review on XON, XXII, CORT, or AKAO then come over to and sign up for your free customized report today. On Tuesday, July 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Five out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, assessed the following Biotechnology equities this morning: Intrexon Corp. (NYSE: XON), 22nd Century Group Inc. (NYSE MKT: XXII), Corcept Therapeutics Inc. (NASDAQ: CORT), and Achaogen Inc. (NASDAQ: AKAO). Learn more about these stocks by registering for free on and accessing the complimentary research reports at: Intrexon 

On Tuesday, shares in Germantown, Maryland-based Intrexon Corp. recorded a trading volume of 595,187. The stock ended at $23.19, rising 0.56% from the last trading session. The Company's shares have gained 9.75% over the previous three months. The stock is trading below its 50-day moving average by 0.83%. Furthermore, shares of Intrexon, which operates in the synthetic biology field in the US, have a Relative Strength Index (RSI) of 47.79. See our free and comprehensive research report on XON at: 22nd Century 

Clarence, New York headquartered 22nd Century Group Inc.'s stock finished yesterday's session 6.80% lower at $1.37. A total volume of 2.34 million shares was traded, which was above their three months average volume of 994.15 thousand shares. The Company's shares advanced 70.89% in the last twelve months and 25.69% on an YTD basis. The stock is trading above its 200-day moving average by 10.91%. Furthermore, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 29.94. XXII free research report PDF is just a click away at: Corcept Therapeutics 

At the close of trading on Tuesday, shares in Menlo Park, California headquartered Corcept Therapeutics Inc. saw a decline of 1.52%, ending the day at $12.34. The stock recorded a trading volume of 775,788 shares. The Company's shares have advanced 33.12% in the previous three months, 107.39% over the last twelve months, and 69.97% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 4.74% and 30.73%, respectively. Moreover, shares of Corcept Therapeutics, which discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have an RSI of 52.30. Sign up for your complimentary report on CORT at: Achaogen 

South San Francisco, California-based Achaogen Inc.'s shares ended the day 9.34% lower at $19.90 with a total trading volume of 2.01 million shares, which was above their three months average of 791.25 thousand shares. The stock has gained 430.67% over the last twelve months, and 52.84% on an YTD basis. The Company's shares are trading above their 200-day moving average by 14.42%. Additionally, shares of Achaogen, which discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections in the US, have an RSI of 33.81. Register for free on and download the latest research report on AKAO at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA